According to latest Research, the global market for CAR T-Cell-Based Drug should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.

By country, China accounted for percent of the global market last year and China’s market share increased from percent to percent. China CAR T-Cell-Based Drug market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029. The United States CAR T-Cell-Based Drug market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.

By segment, Lymphoma grew percent to account for percent of the total market sales, and Multiple Myeloma grew percent.

Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.

This report studies and analyses global CAR T-Cell-Based Drug status and future trends, to help determine the CAR T-Cell-Based Drug market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for CAR T-Cell-Based Drug, and provides market size (US$ million) and Year-over-Year growth, considering 2022 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights

(1) Global CAR T-Cell-Based Drug market size, history data 2018-2023, and forecast data 2024-2029, (US$ million)

(2) Global CAR T-Cell-Based Drug by company, revenue, market share and industry ranking 2018-2023, (US$ million)

(3) China CAR T-Cell-Based Drug by company, revenue, market share and industry ranking 2018-2023, (US$ million)

(4) Global CAR T-Cell-Based Drug key consuming regions, consumption value and demand structure

(5) CAR T-Cell-Based Drug industry chains, upstream, midstream and downstream

Market segment by players, this report covers

Novartis

Gilead Sciences

Bristol-Myers Squibb

J & J

JW Therapeutics

FOSUNKite

CARsgen Therapeutics

Autolus Therapeutics

Sorrento Therapeutics

Mustang Bio

Bluebird Bio

Cellectis

Allogene Therapeutics

Celyad

Market segment by Type, covers

CD19-targeted

BCMA-targeted

Market segment by Application, can be divided into

Lymphoma

Multiple Myeloma

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa

Report Includes:

Chapter 1: to describe CAR T-Cell-Based Drug product scope, global consumption value, China consumption value, development opportunities, challenges, trends, and policies.

Chapter 2: Global CAR T-Cell-Based Drug market share and ranking of major manufacturers, revenue, 2018-2023

Chapter 3: China CAR T-Cell-Based Drug market share and ranking of major manufacturers, revenue, 2018-2023

Chapter 4: CAR T-Cell-Based Drug industry chain, upstream, medium-stream, and downstream.

Chapter 5: Segment by Type, consumption value, percent & CAGR, 2018-2029

Chapter 6: Segment by Application, consumption value, percent & CAGR, 2018-2029

Chapter 7: Segment in regional level, consumption value, percent & CAGR, 2018-2029

Chapter 8: Segment in country level, consumption value, percent & CAGR, 2018-2029

Chapter 9: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, revenue, gross margin.

Chapter 10: Conclusions

1 Market Overview

1.1 CAR T-Cell-Based Drug Definition

1.2 Global CAR T-Cell-Based Drug Market Size and Forecast

1.3 China CAR T-Cell-Based Drug Market Size and Forecast

1.4 China Percentage in Global Market

1.5 CAR T-Cell-Based Drug Market Size: China VS Global Growth Rate, 2018-2029

1.6 CAR T-Cell-Based Drug Market Dynamics

1.6.1 CAR T-Cell-Based Drug Market Drivers

1.6.2 CAR T-Cell-Based Drug Market Restraints

1.6.3 CAR T-Cell-Based Drug Industry Trends

1.6.4 CAR T-Cell-Based Drug Industry Policy

2 Global Leading Players and Market Share

2.1 By Revenue of CAR T-Cell-Based Drug, Global Market Share by Company, 2018-2023

2.2 Global CAR T-Cell-Based Drug Participants, Market Position (Tier 1, Tier 2, and Tier 3)

2.3 Global CAR T-Cell-Based Drug Concentration Ratio

2.4 Global CAR T-Cell-Based Drug Mergers & Acquisitions, Expansion Plans

2.5 Global CAR T-Cell-Based Drug Major Companies Product Type

2.6 Head Office and CAR T-Cell-Based Drug Production Site of Key Manufacturer

3 China Leading Players, Market Share and Ranking

3.1 By Revenue of CAR T-Cell-Based Drug, China Market Share by Company, 2018-2023

3.2 China CAR T-Cell-Based Drug Participants, Market Position (Tier 1, Tier 2, and Tier 3)

4 Industry Chain Analysis

4.1 CAR T-Cell-Based Drug Industry Chain

4.2 CAR T-Cell-Based Drug Upstream Analysis

4.2.1 CAR T-Cell-Based Drug Core Raw Materials

4.2.2 Main Manufacturers of CAR T-Cell-Based Drug Core Raw Materials

4.3 Midstream Analysis

4.4 Downstream Analysis

4.5 CAR T-Cell-Based Drug Production Mode

4.6 CAR T-Cell-Based Drug Procurement Model

4.7 CAR T-Cell-Based Drug Industry Sales Model and Sales Channels

4.7.1 CAR T-Cell-Based Drug Sales Model

4.7.2 CAR T-Cell-Based Drug Typical Distributors

5 Sights by Type

5.1 CAR T-Cell-Based Drug Classification

5.1.1 CD19-targeted

5.1.2 BCMA-targeted

5.2 By Type, Global CAR T-Cell-Based Drug Consumption Value & CAGR, 2018 VS 2022 VS 2029

5.3 By Type, Global CAR T-Cell-Based Drug Consumption Value, 2018-2029

6 Sights by Application

6.1 CAR T-Cell-Based Drug Segment by Application

6.1.1 Lymphoma

6.1.2 Multiple Myeloma

6.2 By Application, Global CAR T-Cell-Based Drug Consumption Value & CAGR, 2018 VS 2022 VS 2029

6.3 By Application, Global CAR T-Cell-Based Drug Consumption Value, 2018-2029

7 Sales Sights by Region

7.1 By Region, Global CAR T-Cell-Based Drug Consumption Value, 2018 VS 2022 VS 2029

7.2 By Region, Global CAR T-Cell-Based Drug Consumption Value, 2018-2029

7.3 North America

7.3.1 North America CAR T-Cell-Based Drug & Forecasts, 2018-2029

7.3.2 By Country, North America CAR T-Cell-Based Drug Market Size Market Share

7.4 Europe

7.4.1 Europe CAR T-Cell-Based Drug Market Size & Forecasts, 2018-2029

7.4.2 By Country, Europe CAR T-Cell-Based Drug Market Size Market Share

7.5 Asia Pacific

7.5.1 Asia Pacific CAR T-Cell-Based Drug Market Size & Forecasts, 2018-2029

7.5.2 By Country/Region, Asia Pacific CAR T-Cell-Based Drug Market Size Market Share

7.6 South America

7.6.1 South America CAR T-Cell-Based Drug Market Size & Forecasts, 2018-2029

7.6.2 By Country, South America CAR T-Cell-Based Drug Market Size Market Share

7.7 Middle East & Africa

8 Sales Sights by Country Level

8.1 By Country, Global CAR T-Cell-Based Drug Market Size & CAGR, 2018 VS 2022 VS 2029

8.2 By Country, Global CAR T-Cell-Based Drug Consumption Value, 2018-2029

8.3 U.S.

8.3.1 U.S. CAR T-Cell-Based Drug Market Size, 2018-2029

8.3.2 By Type, U.S. CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

8.3.3 By Application, U.S. CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

8.4 Europe

8.4.1 Europe CAR T-Cell-Based Drug Market Size, 2018-2029

8.4.2 By Type, Europe CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

8.4.3 By Application, Europe CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

8.5 China

8.5.1 China CAR T-Cell-Based Drug Market Size, 2018-2029

8.5.2 By Type, China CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

8.5.3 By Application, China CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

8.6 Japan

8.6.1 Japan CAR T-Cell-Based Drug Market Size, 2018-2029

8.6.2 By Type, Japan CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

8.6.3 By Application, Japan CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

8.7 South Korea

8.7.1 South Korea CAR T-Cell-Based Drug Market Size, 2018-2029

8.7.2 By Type, South Korea CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

8.7.3 By Application, South Korea CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

8.8 Southeast Asia

8.8.1 Southeast Asia CAR T-Cell-Based Drug Market Size, 2018-2029

8.8.2 By Type, Southeast Asia CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

8.8.3 By Application, Southeast Asia CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

8.9 India

8.9.1 India CAR T-Cell-Based Drug Market Size, 2018-2029

8.9.2 By Type, India CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

8.9.3 By Application, India CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

8.10 Middle East & Africa

8.10.1 Middle East & Africa CAR T-Cell-Based Drug Market Size, 2018-2029

8.10.2 By Type, Middle East & Africa CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

8.10.3 By Application, Middle East & Africa CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

9 Company Profile

9.1 Novartis

9.1.1 Novartis Company Information, Head Office, Market Area and Industry Position

9.1.2 Novartis Company Profile and Main Business

9.1.3 Novartis CAR T-Cell-Based Drug Models, Specifications and Application

9.1.4 Novartis CAR T-Cell-Based Drug Revenue and Gross Margin, 2018-2023

9.1.5 Novartis Recent Developments

9.2 Gilead Sciences

9.2.1 Gilead Sciences Company Information, Head Office, Market Area and Industry Position

9.2.2 Gilead Sciences Company Profile and Main Business

9.2.3 Gilead Sciences CAR T-Cell-Based Drug Models, Specifications and Application

9.2.4 Gilead Sciences CAR T-Cell-Based Drug Revenue and Gross Margin, 2018-2023

9.2.5 Gilead Sciences Recent Developments

9.3 Bristol-Myers Squibb

9.3.1 Bristol-Myers Squibb Company Information, Head Office, Market Area and Industry Position

9.3.2 Bristol-Myers Squibb Company Profile and Main Business

9.3.3 Bristol-Myers Squibb CAR T-Cell-Based Drug Models, Specifications and Application

9.3.4 Bristol-Myers Squibb CAR T-Cell-Based Drug Revenue and Gross Margin, 2018-2023

9.3.5 Bristol-Myers Squibb Recent Developments

9.4 J & J

9.4.1 J & J Company Information, Head Office, Market Area and Industry Position

9.4.2 J & J Company Profile and Main Business

9.4.3 J & J CAR T-Cell-Based Drug Models, Specifications and Application

9.4.4 J & J CAR T-Cell-Based Drug Revenue and Gross Margin, 2018-2023

9.4.5 J & J Recent Developments

9.5 JW Therapeutics

9.5.1 JW Therapeutics Company Information, Head Office, Market Area and Industry Position

9.5.2 JW Therapeutics Company Profile and Main Business

9.5.3 JW Therapeutics CAR T-Cell-Based Drug Models, Specifications and Application

9.5.4 JW Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin, 2018-2023

9.5.5 JW Therapeutics Recent Developments

9.6 FOSUNKite

9.6.1 FOSUNKite Company Information, Head Office, Market Area and Industry Position

9.6.2 FOSUNKite Company Profile and Main Business

9.6.3 FOSUNKite CAR T-Cell-Based Drug Models, Specifications and Application

9.6.4 FOSUNKite CAR T-Cell-Based Drug Revenue and Gross Margin, 2018-2023

9.6.5 FOSUNKite Recent Developments

9.7 CARsgen Therapeutics

9.7.1 CARsgen Therapeutics Company Information, Head Office, Market Area and Industry Position

9.7.2 CARsgen Therapeutics Company Profile and Main Business

9.7.3 CARsgen Therapeutics CAR T-Cell-Based Drug Models, Specifications and Application

9.7.4 CARsgen Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin, 2018-2023

9.7.5 CARsgen Therapeutics Recent Developments

9.8 Autolus Therapeutics

9.8.1 Autolus Therapeutics Company Information, Head Office, Market Area and Industry Position

9.8.2 Autolus Therapeutics Company Profile and Main Business

9.8.3 Autolus Therapeutics CAR T-Cell-Based Drug Models, Specifications and Application

9.8.4 Autolus Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin, 2018-2023

9.8.5 Autolus Therapeutics Recent Developments

9.9 Sorrento Therapeutics

9.9.1 Sorrento Therapeutics Company Information, Head Office, Market Area and Industry Position

9.9.2 Sorrento Therapeutics Company Profile and Main Business

9.9.3 Sorrento Therapeutics CAR T-Cell-Based Drug Models, Specifications and Application

9.9.4 Sorrento Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin, 2018-2023

9.9.5 Sorrento Therapeutics Recent Developments

9.10 Mustang Bio

9.10.1 Mustang Bio Company Information, Head Office, Market Area and Industry Position

9.10.2 Mustang Bio Company Profile and Main Business

9.10.3 Mustang Bio CAR T-Cell-Based Drug Models, Specifications and Application

9.10.4 Mustang Bio CAR T-Cell-Based Drug Revenue and Gross Margin, 2018-2023

9.10.5 Mustang Bio Recent Developments

9.11 Bluebird Bio

9.11.1 Bluebird Bio Company Information, Head Office, Market Area and Industry Position

9.11.2 Bluebird Bio Company Profile and Main Business

9.11.3 Bluebird Bio CAR T-Cell-Based Drug Models, Specifications and Application

9.11.4 Bluebird Bio CAR T-Cell-Based Drug Revenue and Gross Margin, 2018-2023

9.11.5 Bluebird Bio Recent Developments

9.12 Cellectis

9.12.1 Cellectis Company Information, Head Office, Market Area and Industry Position

9.12.2 Cellectis Company Profile and Main Business

9.12.3 Cellectis CAR T-Cell-Based Drug Models, Specifications and Application

9.12.4 Cellectis CAR T-Cell-Based Drug Revenue and Gross Margin, 2018-2023

9.12.5 Cellectis Recent Developments

9.13 Allogene Therapeutics

9.13.1 Allogene Therapeutics Company Information, Head Office, Market Area and Industry Position

9.13.2 Allogene Therapeutics Company Profile and Main Business

9.13.3 Allogene Therapeutics CAR T-Cell-Based Drug Models, Specifications and Application

9.13.4 Allogene Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin, 2018-2023

9.13.5 Allogene Therapeutics Recent Developments

9.14 Celyad

9.14.1 Celyad Company Information, Head Office, Market Area and Industry Position

9.14.2 Celyad Company Profile and Main Business

9.14.3 Celyad CAR T-Cell-Based Drug Models, Specifications and Application

9.14.4 Celyad CAR T-Cell-Based Drug Revenue and Gross Margin, 2018-2023

9.14.5 Celyad Recent Developments

10 Conclusion

11 Appendix

11.1 Research Methodology

11.2 Data Source

11.2.1 Secondary Sources

11.2.2 Primary Sources

11.3 Market Estimation Model

11.4 Disclaimer

Table 1. CAR T-Cell-Based Drug Consumption Value & CAGR: China VS Global, 2018-2029, US$ Million

Table 2. CAR T-Cell-Based Drug Market Restraints

Table 3. CAR T-Cell-Based Drug Market Trends

Table 4. CAR T-Cell-Based Drug Industry Policy

Table 5. Global CAR T-Cell-Based Drug Revenue by Company, 2018-2023, US$ million, Ranked Based on Revenue in 2022

Table 6. Global CAR T-Cell-Based Drug Revenue Share by Company, 2018-2023, Ranked by Data of 2022

Table 7. Global CAR T-Cell-Based Drug Manufacturers Market Concentration Ratio (CR3 and HHI)

Table 8. Global CAR T-Cell-Based Drug Mergers & Acquisitions, Expansion Plans

Table 9. Global CAR T-Cell-Based Drug Major Companies Product Type

Table 10. Head Office and Area Served of Key Players

Table 11. China CAR T-Cell-Based Drug Revenue by Company, 2018-2023, US$ million, Ranked Based on Revenue in 2022

Table 12. China CAR T-Cell-Based Drug Revenue Market Share by Company, 2018-2023

Table 13. Global Key Players of CAR T-Cell-Based Drug Upstream (Raw Materials)

Table 14. Global CAR T-Cell-Based Drug Typical Customers

Table 15. CAR T-Cell-Based Drug Typical Distributors

Table 16. By Type, Global CAR T-Cell-Based Drug Consumption Value & CAGR, 2018 VS 2022 VS 2029, US$ Million

Table 17. By Application, Global CAR T-Cell-Based Drug Consumption Value & CAGR, 2018 VS 2022 VS 2029, US$ Million

Table 18. By Region, Global CAR T-Cell-Based Drug Consumption Value, 2018 VS 2022 VS 2029, US$ Million

Table 19. By Region, Global CAR T-Cell-Based Drug Consumption Value, 2018-2029, US$ Million

Table 20. By Country, Global CAR T-Cell-Based Drug Consumption Value & CAGR, 2018 VS 2022 VS 2029, US$ Million

Table 21. By Country, Global CAR T-Cell-Based Drug Consumption Value, 2018-2029, US$ Million

Table 22. By Country, Global CAR T-Cell-Based Drug Consumption Value Market Share, 2018-2029

Table 23. Novartis Company Information, Head Office, Market Area and Industry Position

Table 24. Novartis Company Profile and Main Business

Table 25. Novartis CAR T-Cell-Based Drug Models, Specifications, and Application

Table 26. Novartis CAR T-Cell-Based Drug Revenue and Gross Margin, US$ Million, 2018-2023

Table 27. Novartis Recent Developments

Table 28. Gilead Sciences Company Information, Head Office, Market Area and Industry Position

Table 29. Gilead Sciences Company Profile and Main Business

Table 30. Gilead Sciences CAR T-Cell-Based Drug Models, Specifications, and Application

Table 31. Gilead Sciences CAR T-Cell-Based Drug Revenue and Gross Margin, US$ Million, 2018-2023

Table 32. Gilead Sciences Recent Developments

Table 33. Bristol-Myers Squibb Company Information, Head Office, Market Area and Industry Position

Table 34. Bristol-Myers Squibb Company Profile and Main Business

Table 35. Bristol-Myers Squibb CAR T-Cell-Based Drug Models, Specifications, and Application

Table 36. Bristol-Myers Squibb CAR T-Cell-Based Drug Revenue and Gross Margin, US$ Million, 2018-2023

Table 37. Bristol-Myers Squibb Recent Developments

Table 38. J & J Company Information, Head Office, Market Area and Industry Position

Table 39. J & J Company Profile and Main Business

Table 40. J & J CAR T-Cell-Based Drug Models, Specifications, and Application

Table 41. J & J CAR T-Cell-Based Drug Revenue and Gross Margin, US$ Million, 2018-2023

Table 42. J & J Recent Developments

Table 43. JW Therapeutics Company Information, Head Office, Market Area and Industry Position

Table 44. JW Therapeutics Company Profile and Main Business

Table 45. JW Therapeutics CAR T-Cell-Based Drug Models, Specifications, and Application

Table 46. JW Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin, US$ Million, 2018-2023

Table 47. JW Therapeutics Recent Developments

Table 48. FOSUNKite Company Information, Head Office, Market Area and Industry Position

Table 49. FOSUNKite Company Profile and Main Business

Table 50. FOSUNKite CAR T-Cell-Based Drug Models, Specifications, and Application

Table 51. FOSUNKite CAR T-Cell-Based Drug Revenue and Gross Margin, US$ Million, 2018-2023

Table 52. FOSUNKite Recent Developments

Table 53. CARsgen Therapeutics Company Information, Head Office, Market Area and Industry Position

Table 54. CARsgen Therapeutics Company Profile and Main Business

Table 55. CARsgen Therapeutics CAR T-Cell-Based Drug Models, Specifications, and Application

Table 56. CARsgen Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin, US$ Million, 2018-2023

Table 57. CARsgen Therapeutics Recent Developments

Table 58. Autolus Therapeutics Company Information, Head Office, Market Area and Industry Position

Table 59. Autolus Therapeutics Company Profile and Main Business

Table 60. Autolus Therapeutics CAR T-Cell-Based Drug Models, Specifications, and Application

Table 61. Autolus Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin, US$ Million, 2018-2023

Table 62. Autolus Therapeutics Recent Developments

Table 63. Sorrento Therapeutics Company Information, Head Office, Market Area and Industry Position

Table 64. Sorrento Therapeutics Company Profile and Main Business

Table 65. Sorrento Therapeutics CAR T-Cell-Based Drug Models, Specifications, and Application

Table 66. Sorrento Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin, US$ Million, 2018-2023

Table 67. Sorrento Therapeutics Recent Developments

Table 68. Mustang Bio Company Information, Head Office, Market Area and Industry Position

Table 69. Mustang Bio Company Profile and Main Business

Table 70. Mustang Bio CAR T-Cell-Based Drug Models, Specifications, and Application

Table 71. Mustang Bio CAR T-Cell-Based Drug Revenue and Gross Margin, US$ Million, 2018-2023

Table 72. Mustang Bio Recent Developments

Table 73. Bluebird Bio Company Information, Head Office, Market Area and Industry Position

Table 74. Bluebird Bio Company Profile and Main Business

Table 75. Bluebird Bio CAR T-Cell-Based Drug Models, Specifications, and Application

Table 76. Bluebird Bio CAR T-Cell-Based Drug Revenue and Gross Margin, US$ Million, 2018-2023

Table 77. Bluebird Bio Recent Developments

Table 78. Cellectis Company Information, Head Office, Market Area and Industry Position

Table 79. Cellectis Company Profile and Main Business

Table 80. Cellectis CAR T-Cell-Based Drug Models, Specifications, and Application

Table 81. Cellectis CAR T-Cell-Based Drug Revenue and Gross Margin, US$ Million, 2018-2023

Table 82. Cellectis Recent Developments

Table 83. Allogene Therapeutics Company Information, Head Office, Market Area and Industry Position

Table 84. Allogene Therapeutics Company Profile and Main Business

Table 85. Allogene Therapeutics CAR T-Cell-Based Drug Models, Specifications, and Application

Table 86. Allogene Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin, US$ Million, 2018-2023

Table 87. Allogene Therapeutics Recent Developments

Table 88. Celyad Company Information, Head Office, Market Area and Industry Position

Table 89. Celyad Company Profile and Main Business

Table 90. Celyad CAR T-Cell-Based Drug Models, Specifications, and Application

Table 91. Celyad CAR T-Cell-Based Drug Revenue and Gross Margin, US$ Million, 2018-2023

Table 92. Celyad Recent Developments

List of Figures

Figure 1. CAR T-Cell-Based Drug Picture

Figure 2. Global CAR T-Cell-Based Drug Consumption Value, (US$ million) & (2018-2029)

Figure 3. China CAR T-Cell-Based Drug Consumption Value, (US$ million) & (2018-2029)

Figure 4. By Consumption Value, China CAR T-Cell-Based Drug Market Share of Global, 2018-2029

Figure 5. Global CAR T-Cell-Based Drug Market Share by Company, (Tier 1, Tier 2, and Tier 3), 2022

Figure 6. China CAR T-Cell-Based Drug Key Participants, Market Share, 2022

Figure 7. CAR T-Cell-Based Drug Industry Chain

Figure 8. CAR T-Cell-Based Drug Procurement Model

Figure 9. CAR T-Cell-Based Drug Sales Model

Figure 10. CAR T-Cell-Based Drug Sales Channels, Direct Sales, and Distribution

Figure 11. CD19-targeted

Figure 12. BCMA-targeted

Figure 13. By Type, Global CAR T-Cell-Based Drug Consumption Value, 2018-2029, US$ Million

Figure 14. By Type, Global CAR T-Cell-Based Drug Consumption Value Market Share, 2018-2029

Figure 15. Lymphoma

Figure 16. Multiple Myeloma

Figure 17. By Application, Global CAR T-Cell-Based Drug Consumption Value, 2018-2029, US$ Million

Figure 18. By Application, Global CAR T-Cell-Based Drug Consumption Value Market Share, 2018-2029

Figure 19. By Region, Global CAR T-Cell-Based Drug Consumption Value Market Share, 2018-2029

Figure 20. North America CAR T-Cell-Based Drug Consumption Value & Forecasts, 2018-2029, US$ Million

Figure 21. By Country, North America CAR T-Cell-Based Drug Consumption Value Market Share, 2022

Figure 22. Europe CAR T-Cell-Based Drug Consumption Value & Forecasts, 2018-2029, US$ Million

Figure 23. By Country, Europe CAR T-Cell-Based Drug Consumption Value Market Share, 2022

Figure 24. Asia Pacific CAR T-Cell-Based Drug Consumption Value & Forecasts, 2018-2029, US$ Million

Figure 25. By Country/Region, Asia Pacific CAR T-Cell-Based Drug Consumption Value Market Share, 2022

Figure 26. South America CAR T-Cell-Based Drug Consumption Value & Forecasts, 2018-2029, US$ Million

Figure 27. By Country, South America CAR T-Cell-Based Drug Consumption Value Market Share, 2022

Figure 28. Middle East & Africa CAR T-Cell-Based Drug Consumption Value & Forecasts, 2018-2029, US$ Million

Figure 29. U.S. CAR T-Cell-Based Drug Consumption Value, 2018-2029, US$ Million

Figure 30. By Type, U.S. CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

Figure 31. By Application, U.S. CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

Figure 32. Europe CAR T-Cell-Based Drug Consumption Value, 2018-2029, US$ Million

Figure 33. By Type, Europe CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

Figure 34. By Application, Europe CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

Figure 35. China CAR T-Cell-Based Drug Consumption Value, 2018-2029, US$ Million

Figure 36. By Type, China CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

Figure 37. By Application, China CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

Figure 38. Japan CAR T-Cell-Based Drug Consumption Value, 2018-2029, US$ Million

Figure 39. By Type, Japan CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

Figure 40. By Application, Japan CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

Figure 41. South Korea CAR T-Cell-Based Drug Consumption Value, 2018-2029, US$ Million

Figure 42. By Type, South Korea CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

Figure 43. By Application, South Korea CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

Figure 44. Southeast Asia CAR T-Cell-Based Drug Consumption Value, 2018-2029, US$ Million

Figure 45. By Type, Southeast Asia CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

Figure 46. By Application, Southeast Asia CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

Figure 47. India CAR T-Cell-Based Drug Consumption Value, 2018-2029, US$ Million

Figure 48. By Type, India CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

Figure 49. By Application, India CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

Figure 50. Middle East & Africa CAR T-Cell-Based Drug Consumption Value, 2018-2029, US$ Million

Figure 51. By Type, Middle East & Africa CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

Figure 52. By Application, Middle East & Africa CAR T-Cell-Based Drug Consumption Value Market Share, 2022 VS 2029

Figure 53. Research Methodology

Figure 54. Breakdown of Primary Interviews

Figure 55. Bottom-up and Top-down Approaches

Figure 56. Top-down Approaches

Methodology/Research Approach

This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.

Research Programs/Design

Historical Data (2015-2019)	Industry Trends Competitive Landscape By Company Expansion Mergers and Acquisitions Market Segment by Type by Application By Regions/ Geography	Value Status and Outlook Value for Major Players Market Share Growth Rate Present Situation Analysis Value Market Share Growth Rate Present Situation Analysis
Influencing Factors	Market Environment Government Policy Technological Changes Market Risks	Market Drivers Growing Demand of Downstream Reduction in Cost
Market Forecast (2021-2026)	Overall Size by Type by Application By Regions/Geography	Key Data (Value) Market Share Growth Rate CAGR (2021-2026)

Market Size Estimation

Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).

The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.

Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.

All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report

The following figure shows an illustrative representation of the overall market size estimation process used for this study.

Market Breakdown and Data Triangulation

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.

Data Source

Secondary Sources

Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.

Market Size	Segmental value Geographic Penetration Product Adoption Rate for Different market	Journals, Websites, and Press Releases Annual Reports and SEC Filings Company Websites and Press Releases Public and Paid Databases Market Intellix Data Repository
Market Position of Top Company	Product Financials Geographic value Mix Total Company value Business/Segmental value Mix
Qualitative Analysis	Influence Factors Market Potential Market Risks and Opportunities Industry Trends Geographical Features Government Policies	Company Websites and Press Releases Public and Paid Databases Annual Reports Industry Associations Market Intellix Data Repository

Primary Sources

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.

Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.

Key Executives Interviewed

Key Data Information from Primary Sources

Primary Sources	Parameters	Key Data
Market Segments(by Application, by Type)	Value by Type Status and Forecast Value by Application Value by Regions, Status and Forecast (2021-2026)	Value Market Share by Type Value Growth Rate by Type Value by Application Percentage and Growth Rate by Application Value Growth Rate and Market Share by Regions Market Size Status and Forecast (2021-2026)
Total Market	Overall Size, Status and Forecast	Market Size Status and Forecast (2021-2026)